Journal article
Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice
Journal of pharmaceutical sciences, Vol.108(10), pp.3434-3442
10/2019
DOI: 10.1016/j.xphs.2019.05.028
PMID: 31163185
Abstract
Small-molecule tyrosine kinase inhibitors (TKIs) are novel anticancer agents with enhanced selectivity and superior safety profiles than conventional chemotherapeutics. A major shortcoming in TKI therapy is the development of acquired resistance. An important resistance mechanism is reduced intracellular drug accumulation due to an overexpression of efflux transporters such as P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) in cancer cells. TKIs have dual roles as substrates and inhibitors of Pgp and BCRP; thus, combination TKI therapy could potentially reverse efflux transporter-mediated TKI resistance. In the present study, the effect of 14 TKIs on Pgp-, Bcrp1-, and BCRP-mediated afatinib efflux was investigated in vitro. Nilotinib was a potent inhibitor of Pgp, Bcrp1, and BCRP, with EC50 values of 2.22, 2.47, and 0.692 μM, respectively. Consequently, the pharmacokinetics of afatinib with and without the coadministration of nilotinib was determined in mice plasma and various tissues. Nilotinib increased afatinib AUC by 188% in plasma, and this altered tissue AUC by −38.8% to +221%. Nilotinib also decreased the clearance of afatinib by 65.3%, from 609 to 211 mL/h. Further studies are warranted to assess nilotinib’s chemosensitizing effect in tumor xenograft models.
Details
- Title: Subtitle
- Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice
- Creators
- Ronilda R. D’Cunha - The Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52246Daryl J. Murry - University of Nebraska Medical CenterGuohua An - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Journal of pharmaceutical sciences, Vol.108(10), pp.3434-3442
- DOI
- 10.1016/j.xphs.2019.05.028
- PMID
- 31163185
- NLM abbreviation
- J Pharm Sci
- ISSN
- 0022-3549
- eISSN
- 1520-6017
- Publisher
- Elsevier Inc
- Grant note
- DOI: 10.13039/100001797, name: PhRMA Foundation, award: IRG-77-004-34; DOI: 10.13039/100000048, name: American Cancer Society
- Language
- English
- Date published
- 10/2019
- Academic Unit
- Pharmaceutical Sciences and Experimental Therapeutics; Holden Comprehensive Cancer Center
- Record Identifier
- 9984365900602771
Metrics
15 Record Views